Premier Alternatives

Delfi Diagnostics

Palo Alto, CA · Founded 2019 · Privately Held (backing)

Developer of a blood test system designed for the early detection of cancer. Delfi Diagnostics is based in Palo Alto, CA and was founded in 2019. Its last reported valuation was $725 million in Jun 2024. It has raised $466 million across 1 recorded round; the latest was a $34.3 million debt round in Dec 2025.

Last reported valuation
$725.0M
Oct 2026
Priced at
—
Total raised
$465.9M
Last round
Debt
Dec 2025

Delfi Diagnostics key facts

as of Oct 2026
  • Developer of a blood test system designed for the early detection of cancer.
  • Delfi Diagnostics is valued at approximately $725.0M as of Oct 2026 (last reported valuation).
  • It has raised $465.9M across 1 recorded rounds; the latest was Debt ($34.3M) in Dec 2025.
  • Notable investors include Menlo Ventures, OrbiMed, Mirae Asset Capital, Point72 Ventures, T. Rowe Price Group — 27 tracked in total.
  • Delfi Diagnostics has filed 1 Form D with the SEC, most recently Dec 2025 ($34.3M sold to 50 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$725.0M

Delfi Diagnostics's last reported valuation, Jun 2024. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Delfi Diagnostics with a free account
  • ·The complete investor list: 27 names
  • ·Watch Delfi Diagnostics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Delfi Diagnostics funding rounds

1 rounds
Dec 2025Debt$34.3MSEC filing▮
Full funding history →

Delfi Diagnostics valuation

Delfi Diagnostics's last reported valuation was $725 million in Jun 2024. No priced round, secondary trade or fund mark has surfaced since.

How much has Delfi Diagnostics raised?

Delfi Diagnostics has raised $466 million in total; 1 of its rounds is on record. The largest on record was a $34.3 million debt round in Dec 2025.

Delfi Diagnostics has filed 1 Form D with the SEC, most recently in Dec 2025 ($34.3 million sold to 50 investors).

Delfi Diagnostics investors

27 investors are on record for Delfi Diagnostics, including Menlo Ventures, OrbiMed, Mirae Asset Capital and Point72 Ventures. By type, the record holds 10 venture capital firms, 1 family office and 1 hedge fund. The debt round in Dec 2025 drew 50 investors.

About Delfi Diagnostics

Developer of a blood test system designed for the early detection of cancer. The company's medical system uses machine learning to specialize in the research and development of innovative blood and genome testing for the detection and interception of cancer when it is curable, enabling healthcare professionals to detect previously unrecognized cancer-associated cell-free DNA fragments and provide efficient treatments for a speedy recovery.

Sector
Healthcare
HQ
Palo Alto, CA, United States
Founded
2019
Employees
175
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.